Nuvation Bio
NEW YORK, NY · Founded 2018 · CIK 0001829093 · Biotech · Public
Oncology therapeutics developed through proprietary drug discovery and development platform
nuvationbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $275M
- 1 Form D · Oct 2020
- 72 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 3 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021202220232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $275,348,195 |
Form D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2782 | Legend Biotech Corp | — | $350M |
| 2783 | Sensei Biotherapeutics, Inc. | — | $349M |
| 2784 | X4 Pharmaceuticals | — | $313M |
| 2785 | Nuvation Bio | — | $275M |
| 2786 | CELL REPROGRAMMING & THERAPEUTICS LLC | — | — |
| 2787 | Veradermics | — | $269M |
| 2788 | Avalyn Pharma | — | $242M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung CancerPRNewswire
Founders & Team
- Robert BazemoreDirector
- Kim BlickenstaffDirector
- Michelle DoigDirector
- Kathryn FalbergDirector
- David Hung, M.D.Director · Executive Officer
- Claudio NessiDirector
- W. VernonDirector
- Daniel WelchDirector
Patents
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
- Method For Producing 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE Compoundsapplication
- Heterocyclic Compounds As Bet Inhibitorsapplication
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
- Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
- Heterocyclic Compounds As Bet Inhibitorsapplication
- Heterocyclic Compounds As Bet Inhibitorsapplication
- SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORSapplication
- Treating Cancers With A Cyclin-dependent Kinase Inhibitorapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.